SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

Search

Innate Pharma SA

Închisă

1.91 0.53

Rezumat

Modificarea prețului

24h

Curent

Minim

1.9

Maxim

1.91

Indicatori cheie

By Trading Economics

Venit

57K

-25M

Vânzări

-8M

4.3M

EPS

-0.3

Marjă de profit

-570.732

Angajați

181

EBITDA

2.5M

-23M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+61.67% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

29M

183M

Deschiderea anterioară

1.38

Închiderea anterioară

1.91

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

Innate Pharma SA Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

6 iun. 2025, 14:31 UTC

Câștiguri

New York State Retirement Fund Posts 5.84% Annual Investment Return

6 iun. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 iun. 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 iun. 2025, 20:33 UTC

Câștiguri

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 iun. 2025, 19:36 UTC

Market Talk

Oil Futures Post Solid Weekly Gains -- Market Talk

6 iun. 2025, 19:28 UTC

Market Talk

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6 iun. 2025, 18:46 UTC

Market Talk

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6 iun. 2025, 18:02 UTC

Market Talk

U.S. Oil Rig Count Continues to Decline -- Market Talk

6 iun. 2025, 16:35 UTC

Câștiguri

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 iun. 2025, 16:34 UTC

Câștiguri

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 iun. 2025, 16:21 UTC

Market Talk

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6 iun. 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 iun. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 iun. 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

6 iun. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6 iun. 2025, 16:07 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

6 iun. 2025, 16:07 UTC

Market Talk

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6 iun. 2025, 15:53 UTC

Market Talk

Mexican Inflation Seen Rising in May -- Market Talk

6 iun. 2025, 15:36 UTC

Market Talk

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6 iun. 2025, 15:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 iun. 2025, 15:33 UTC

Market Talk

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6 iun. 2025, 15:16 UTC

Market Talk

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6 iun. 2025, 15:05 UTC

Market Talk

Silver at its Highest In Nearly 15 Years -- Market Talk

6 iun. 2025, 14:35 UTC

Market Talk

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6 iun. 2025, 14:28 UTC

Market Talk

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6 iun. 2025, 14:28 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 iun. 2025, 14:28 UTC

Market Talk

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6 iun. 2025, 14:15 UTC

Market Talk

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6 iun. 2025, 14:12 UTC

Câștiguri

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6 iun. 2025, 14:09 UTC

Câștiguri

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Comparație

Modificare preț

Innate Pharma SA Așteptări

Obiectiv de preț

By TipRanks

61.67% sus

Prognoză pe 12 luni

Medie 3.104 EUR  61.67%

Maxim 3.1 EUR

Minim 3.1 EUR

În baza a 1 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruInnate Pharma SA - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

1 ratings

0

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

1.91 / 2.1Suport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Weak Bullish Evidence

Termen lung

Bullish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Innate Pharma SA

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.